Amgen Inc. $AMGN Shares Bought by Calamos Advisors LLC

Calamos Advisors LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,874 shares of the medical research company’s stock after buying an additional 1,394 shares during the quarter. Calamos Advisors LLC’s holdings in Amgen were worth $29,453,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Quest 10 Wealth Builders Inc. grew its stake in Amgen by 220.0% in the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after buying an additional 55 shares in the last quarter. Wellington Altus USA Inc. boosted its holdings in shares of Amgen by 72.3% in the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after acquiring an additional 34 shares during the period. Nvwm LLC boosted its holdings in shares of Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after acquiring an additional 66 shares during the period. PFS Partners LLC grew its position in shares of Amgen by 95.5% in the third quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 42 shares in the last quarter. Finally, TOWER TRUST & INVESTMENT Co purchased a new position in shares of Amgen in the third quarter valued at $38,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported quarterly earnings and revenue above expectations, with revenue up 8.5% year over year. Its earnings-call discussion also emphasized growth and pipeline momentum, supporting the case for continued expansion. Amgen Earnings Call Highlights Growth, Pipeline Momentum
• Positive Sentiment: A large real-world study found Repatha lowered heart-attack risk by 20% versus ezetimibe in patients with heart disease. The findings could strengthen the drug’s clinical and commercial position. Repatha real-world study
• Positive Sentiment: Scotiabank reiterated a Buy view and set a $530 price target; UBS also maintains a Buy rating with a $530 target. Separately, ETFs bought a net $79.8 million of AMGN shares in Wednesday’s session. Scotiabank price target ETF holdings
• Neutral Sentiment: Analyst opinions remain divided: Leerink Partners and Guggenheim have Hold/neutral ratings, while Scotiabank and UBS are more optimistic. The differing views suggest debate about how much of Amgen’s recent gains are already reflected in its valuation. Leerink Partners rating
• Negative Sentiment: Freedom Broker downgraded Amgen to Hold, adding to the cautious analyst commentary and potentially tempering enthusiasm after the recent rally. Freedom Broker downgrade

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. The trade was a 16.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

Shares of AMGN traded up $0.14 during trading hours on Friday, reaching $460.42. 2,579,312 shares of the company’s stock traded hands, compared to its average volume of 2,619,150. Amgen Inc. has a 12 month low of $312.39 and a 12 month high of $483.99. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a market cap of $248.92 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 3.41 and a beta of 0.43. The firm’s 50 day simple moving average is $422.43 and its 200-day simple moving average is $378.19.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm posted $5.64 earnings per share. Equities analysts expect that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen’s dividend payout ratio (DPR) is 58.47%.

Analyst Ratings Changes

Several brokerages have commented on AMGN. Oppenheimer restated an “outperform” rating on shares of Amgen in a research note on Friday, October 23rd. Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday, October 18th. Robert W. Baird boosted their price objective on shares of Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group upped their target price on shares of Amgen from $384.00 to $440.00 and gave the stock a “hold” rating in a report on Wednesday. Finally, UBS Group upped their target price on shares of Amgen from $470.00 to $530.00 and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $420.80.

About Amgen

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases.

The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally.

Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A.